Bristol Myers Squibb (NYSE: BMY)‘s stock had its “buy” rating reiterated by investment analysts at TheStreet in a note issued to investors on Monday.
The analysts wrote, “Bristol-Myers Squibb Company (BMY) has been reiterated by TheStreet Ratings as a buy with a ratings score of A- . The company’s strengths can be seen in multiple areas, such as its expanding profit margins, solid stock price performance, growth in earnings per share, largely solid financial position with reasonable debt levels by most measures and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow.”
Shares of Bristol Myers Squibb (NYSE: BMY) opened at 38.96 on Monday. Bristol Myers Squibb has a one year low of $30.64 and a one year high of $38.98. The stock’s 50-day moving average is currently $37.00. The company has a market cap of $63.791 billion and a P/E ratio of 33.59.
Bristol Myers Squibb (NYSE: BMY) last released its earnings data on Thursday, January 24th. The company reported $0.47 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.42 by $0.05. The company had revenue of $4.19 billion for the quarter, compared to the consensus estimate of $4.14 billion. During the same quarter last year, the company posted $0.53 earnings per share. Bristol Myers Squibb’s revenue was down 23.2% compared to the same quarter last year. Bristol Myers Squibb has set its FY13 guidance at $1.78-1.88 EPS. Analysts expect that Bristol Myers Squibb will post $1.84 EPS for the current fiscal year.
BMY has been the subject of a number of other recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of Bristol Myers Squibb in a research note to investors on Wednesday, March 13th. They now have a $40.00 price target on the stock. Separately, analysts at William Blair initiated coverage on shares of Bristol Myers Squibb in a research note to investors on Tuesday, March 5th. They set an “outperform” rating on the stock. Finally, analysts at Sanford C. Bernstein reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research note to investors on Tuesday, March 5th. They now have a $34.00 price target on the stock.
Seven investment analysts have rated the stock with a buy rating, one has issued an overweight rating, fourteen have assigned a hold rating, and one has given a sell rating to the company. The stock presently has a consensus rating of “overweight” and a consensus target price of $36.63.
The company also recently declared a quarterly dividend, which is scheduled for Wednesday, May 1st. Investors of record on Friday, April 5th will be given a dividend of $0.35 per share. This represents a $1.40 dividend on an annualized basis and a yield of 3.59%. The ex-dividend date of this dividend is Wednesday, April 3rd.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis.
To view TheStreet’s full report, visit www.thestreetratings.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.